ES2509959T3 - Métodos y composiciones - Google Patents

Métodos y composiciones Download PDF

Info

Publication number
ES2509959T3
ES2509959T3 ES12151953.2T ES12151953T ES2509959T3 ES 2509959 T3 ES2509959 T3 ES 2509959T3 ES 12151953 T ES12151953 T ES 12151953T ES 2509959 T3 ES2509959 T3 ES 2509959T3
Authority
ES
Spain
Prior art keywords
exposure
polypeptide
peptides
nucleic acid
bound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12151953.2T
Other languages
English (en)
Other versions
ES2509959T5 (en
Inventor
Gregory Winter
Christian Heinis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bicycle Therapeutics PLC
Original Assignee
Bicycle Therapeutics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40792924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2509959(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0802079.4A external-priority patent/GB0802079D0/en
Priority claimed from GB0818399A external-priority patent/GB0818399D0/en
Application filed by Bicycle Therapeutics PLC filed Critical Bicycle Therapeutics PLC
Application granted granted Critical
Publication of ES2509959T3 publication Critical patent/ES2509959T3/es
Publication of ES2509959T5 publication Critical patent/ES2509959T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Colección de polipéptidos codificados genéticamente de complejos que comprenden un ácido nucleico que codifica un polipéptido, en donde: (i) el polipéptido codificado por el ácido nucleico está unido al ácido nucleico; (ii) un compuesto conector unido a dicho polipéptido; (iii) el compuesto conector está unido al polipéptido mediante al menos tres enlaces covalentes independientes; y (iv) la colección es una genoteca exposición de ARNm, exposición de ADN, exposición en levadura, exposición en ribosomas o exposición en bacterias.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
E12151953
02-10-2014
calicreína plasmática humana (<2000 Da). Nuestro mejor inhibidor (PK15) con Ki = 1,5 nM interrumpe con eficacia la vía de la coagulación intrínseca en el plasma humano analizado ex vivo, y era muy específico: no inhibía la calicreína plasmática de ratón ni las proteasas plasmáticas homólogas humanas factor XIa y trombina.
Nuestro repertorio se construyó a partir de péptidos de 17 restos con tres cisteínas, separadas entre sí por seis
5 aminoácidos aleatorios. Después de la conjugación con TBMB, se espera que los péptidos formen dos lazos de seis restos unidos a un núcleo de mesitileno, como se confirmó realmente gracias a la estructura del inhibidor de la calicreína PK15 resuelto por RMN (figura 14). Tales péptidos policíclicos deben tener ventajas tanto sobre los péptidos con puentes disulfuro como con los lineales. Las ventajas de los péptidos policíclicos sobre los péptidos con puentes disulfuro son que los enlaces covalentes azufre-carbono, una vez que se forman, son inertes para el
10 intercambio18, y también son estables en un entorno reductor18. La ventaja de los péptidos policíclicos sobre los péptidos lineales es que están interconectados y más constreñidos. Esto tiene dos consecuencias principales: (a) los péptidos constreñidos se espera que se unan más estrechamente a las dianas (debido a la menor pérdida de entropía conformacional). Nuestra revisión de la bibliografía sobre inhibidores peptídicos que se han aislado por exposición en fagos muestra que la mayoría contienen puentes disulfuro y tienen constantes de inhibición del orden
15 micromolar (tabla 3).
Tabla 3: Inhibidores peptídicos seleccionados en fagos. Se indican la secuencia de los péptidos, la diana de la enzima y la afinidad de unión. Los restos de cisteína que forman puentes disulfuro están subrayados.
Diana
Secuencia peptídica Afinidad Referencia
Antígeno prostático específico (PSA)
imagen36 KD = 2,9 µM 1
Calicreína 2 humana
imagen37 CI50 = 3,4 µM 2
Activador del plasminógeno de tipo urocinasa (uPA)
imagen38 Ki = 6,7 µM 3
Activador del plasminógeno de tipo urocinasa (uPA)
imagen39 Ki = 0,4 µM 4
Quimotripsina
imagen40 Ki = 1 µM 5
TF-fVII
imagen41 CI50 = 1,5 nM 6
Enzima convertidora de la angiotensina 2 (ACE2)
imagen42 KI = 2,8 nM 7
ErbB-2
imagen43 Ki = 30 µM 8
Ureasa
imagen44 CI50 = 30 µM 9
Lipasa pancreática
imagen45 CI50 = 16 µM 10
β-Lactamasa
imagen46 CI50 = 9 µM 11
DNasa II
imagen47 KI = 0,2 µM 12
Sólo dos inhibidores peptídicos fueron tan potentes como la PK15; ambos contenían un puente disulfuro y al menos
20 dos restos de triptófano19-20 . Esto sugiere que (a) la conformación constreñida y la posibilidad de formar interacciones hidrófobas son clave para estas afinidades elevadas; (b) los péptidos constreñidos (e interconectados) también deben ser más resistentes a la escisión y/o inactivación que los péptidos lineales. De hecho, en nuestro trabajo se escindió uno de los lazos del inhibidor PK15 después de la incubación prolongada con la calicreína plasmática humana, pero permaneció intacta y activa.
25 Los conjugados policíclicos se prestan a la ingeniería genética y química. La masa molecular del PK15 (1939,4 Da) es mayor que la de varios fármacos macrocíclicos peptídicos (tabla 2), pero sería posible utilizar lazos más pequeños. Por ejemplo, al alterar el espaciado de las cisteínas, se varía directamente la longitud del lazo, o incluso 37
E12151953
02-10-2014
se añaden segmentos adicionales a los extremos de los péptidos. Tabla 2. Comparación de tamaños de los fármacos macrocíclicos.
Nombre
Tamaño del ciclo o de los ciclos Masa molecular (Da) Aplicación
Actinomicina
16,16 1255,42 Antineoplásico
Amfotericina B
38 924,08 Antimicótico
Azitromicina
15 748,88 Antibiótico
Caspofungina
21 1093,31 Antimicótico
Ciclosporina
32 1202,61 Inmunodepresor
Daptomicina
31 1619,71 Antibiótico
Eritromicina
14 733,93 Antibiótico
Ixabepilona
16 506,70 Antineoplásico
Ocreótido
20 1019,24 Hormona
Oxitocina
20 1007,19 Hormona
Polimixina B
23 1301,56 Antibiótico
Rapamicina
29 914,17 Inmunodepresor
Rifabutina
27 847,01 Antibiótico
Vancomicina
16, 16, 12 1449,30 Antibiótico
Otras variaciones podrían incluir la mutagénesis de los lazos (como con la maduración de la afinidad de PK15); la
5 escisión proteolítica de uno o ambos lazos para generar segmentos peptídicos «ramificados» en las cisteínas; conjugación química en los extremos del péptido naciente después de la escisión de lazo21; o el uso de variaciones en los núcleos orgánicos. Por ejemplo, un núcleo orgánico más grande, o uno con más grupos funcionales podría interaccionar más extensivamente con los lazos o con la diana, y también se podrían utilizar para introducir funciones completamente nuevas, tales como la fluorescencia. Si se realizasen estas operaciones sobre el
10 conjugado expuesto en fagos, se podrían seleccionar las variaciones mediante un proceso reiterativo. Dado que los conjugados peptídicos también son adecuados para la síntesis química, se podrían introducir sintéticamente más variaciones (tales como la sustitución mediante aminoácidos no naturales).
Los inhibidores de la calicreína plasmática humana se han desarrollado clínicamente para el tratamiento del angioedema hereditario y para la intervención quirúrgica para la derivación coronaria, pero se ha demostrado que es
15 difícil fabricar moléculas pequeñas que sean específicas de la calicreína (revisado en22,23). El hecho de que nosotros obtengamos fácilmente un inhibidor muy específico y de gran afinidad mediante la selección reiterativa de conjugados peptídicos policíclicos sobre los fagos indica que esta estrategia está bien encaminada.
Materiales y métodos
Modificación química con TBMB de los repertorios peptídicos sobre los fagos
20 Las genotecas de péptidos en fagos que se basan en el plásmido fdg3p0ss2116 se clonaron y se produjeron como se describe más adelante. Típicamente, los fagos purificados con PEG a 1011-1012 u.t. se redujeron en 20 ml de NH4HCO3 a 20 mM, pH 8 con TCEP a 1 mM a 42 ºC durante 1 hora. Los fagos se centrifugaron a 4000 rpm en un filtro Vivaspin 20 (masa molecular límite de 10 000) para reducir el volumen del tampón de reducción a 1 ml y se lavó dos veces con 10 ml de tampón de reacción enfriado en hielo (NH4HCO3 a 20 mM y EDTA a 5 mM, pH 8). El
38
imagen48
imagen49
imagen50
imagen51
imagen52

Claims (1)

  1. imagen1
    imagen2
ES12151953T 2008-02-05 2009-02-04 Methods and compositions Active ES2509959T5 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0802079.4A GB0802079D0 (en) 2008-02-05 2008-02-05 Method and compositions
GB0802079 2008-02-05
GB0818399A GB0818399D0 (en) 2008-10-08 2008-10-08 Methods and compositions
GB0818399 2008-10-08

Publications (2)

Publication Number Publication Date
ES2509959T3 true ES2509959T3 (es) 2014-10-20
ES2509959T5 ES2509959T5 (en) 2024-12-19

Family

ID=40792924

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09708496T Active ES2383191T3 (es) 2008-02-05 2009-02-04 Métodos y composiciones
ES12151953T Active ES2509959T5 (en) 2008-02-05 2009-02-04 Methods and compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES09708496T Active ES2383191T3 (es) 2008-02-05 2009-02-04 Métodos y composiciones

Country Status (11)

Country Link
US (3) US8680022B2 (es)
EP (5) EP2653544A1 (es)
JP (2) JP6074574B2 (es)
AT (1) ATE555200T1 (es)
AU (1) AU2009211253B2 (es)
CA (1) CA2714477C (es)
DK (2) DK2474613T3 (es)
ES (2) ES2383191T3 (es)
PL (1) PL2257624T3 (es)
PT (1) PT2257624E (es)
WO (1) WO2009098450A2 (es)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0913775D0 (en) * 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
GB0914110D0 (en) * 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
JP2013518807A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 多重特異性ペプチド
JP2013518558A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 構造化されたペプチドプロセシング
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
CN103403160A (zh) * 2010-08-13 2013-11-20 G·克里斯蒂安森 修饰肽的展示
GB201013980D0 (en) 2010-08-20 2010-10-06 Ecole Polytech Bicyclic uPA inhibitors
RU2657440C2 (ru) 2011-06-30 2018-06-13 Джензим Корпорейшн Ингибиторы т-клеточной активации
JP6254527B2 (ja) * 2011-10-07 2017-12-27 バイサイクル・セラピューティクス・リミテッド 構造化ポリペプチドの特異性のモジュレーション
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
JP2015508638A (ja) 2012-02-03 2015-03-23 ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ ファージディスプレイを用いてペプチド誘導体ライブラリーを定量化するための方法
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
AU2013260123A1 (en) 2012-05-10 2014-11-13 Massachusetts Institute Of Technology Agents for influenza neutralization
AU2013299986B2 (en) 2012-08-07 2018-05-17 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
EP3456734B1 (en) 2012-10-04 2022-01-05 Research Development Foundation Serine protease molecules and therapies
AU2013350802B2 (en) * 2012-11-30 2016-07-14 Novartis Ag Methods for making conjugates from disulfide-containing proteins
GB201306623D0 (en) * 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
ES2705068T3 (es) 2013-05-23 2019-03-21 Ohio State Innovation Foundation Síntesis química y cribado de bibliotecas de péptidos bicíclicos
US10526375B2 (en) 2013-06-05 2020-01-07 Massachusetts Institute Of Technology Human Adaptation of H7 HA
JP6474404B2 (ja) 2013-08-14 2019-02-27 ウィリアム マーシュ ライス ユニバーシティＷｉｌｌｉａｍ Ｍａｒｓｈ Ｒｉｃｅ Ｕｎｉｖｅｒｓｉｔｙ ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用
WO2015063465A2 (en) * 2013-10-28 2015-05-07 Bicycle Therapeutics Limited Novel polypeptides
AU2015217149B2 (en) 2014-02-11 2020-09-10 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
WO2015166036A1 (en) 2014-05-02 2015-11-05 Morphosys Ag Peptide libraries
GB201413086D0 (en) 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
EP3209819B1 (en) 2014-10-22 2024-02-14 The Governors Of The University Of Alberta Genetic encoding of chemical post-translational modification for phage-displayed libraries
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
KR101693665B1 (ko) * 2014-11-13 2017-01-06 목포해양대학교 산학협력단 설치와 철거가 용이한 구조를 가지는 기초의 세굴방지장치 및 이를 이용한 기초의 세굴방지방법
MA41022A (fr) 2014-11-24 2017-10-03 Shire Human Genetic Therapies Ciblage lysosomial et utilisations correspondantes
JP6609099B2 (ja) * 2014-12-10 2019-11-20 キヤノン株式会社 放射線検出装置、及び放射線検出シート
DK3237614T3 (da) 2014-12-22 2019-09-09 Lanthiopep Bv Nye fremgangsmåder til fremvisning af cyklisk peptider på overfladen af bakteriofagpartikler
WO2016170101A1 (en) * 2015-04-23 2016-10-27 F. Hoffmann-La Roche Ag Cow antibody scaffold polypeptide method and composition
JP2015214568A (ja) * 2015-07-13 2015-12-03 バイスクル・セラピューティクス・リミテッド 多重特異性ペプチド
DK3417058T3 (da) 2016-02-16 2021-11-15 Res Found Dev Sortase-modificerede molekyler og anvendelser deraf
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
CN109312324B (zh) * 2016-06-07 2022-08-16 株式会社钟化 核糖体展示复合体及其制造方法
CA3043464A1 (en) 2016-11-09 2018-05-17 Ohio State Innovation Foundation Di-sulfide containing cell penetrating peptides and methods of making and using thereof
US10913773B2 (en) 2016-11-22 2021-02-09 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
US11352394B2 (en) 2016-11-22 2022-06-07 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
WO2018096365A1 (en) 2016-11-27 2018-05-31 Bicyclerd Limited Methods for treating cancer
CA3046171A1 (en) 2016-12-06 2018-06-14 Stichting Voor De Technische Wetenschappen Multicyclic peptides and methods for their preparation
EP3559018A1 (en) * 2016-12-23 2019-10-30 Bicyclerd Limited Peptide derivatives having novel linkage structures
MX2019007367A (es) * 2016-12-23 2020-01-27 Bicycletx Ltd Ligandos de peptido para enlace a mt1-mmp.
ES2985986T3 (es) 2017-01-06 2024-11-08 Bicyclerd Ltd Conjugado biciclo para tratar el cáncer
CA3087881A1 (en) 2017-01-17 2018-07-26 Michael David FORREST Therapeutic inhibitors of the reverse mode of atp synthase
EP3577258B1 (en) 2017-01-31 2024-11-27 48Hour Discovery Inc. Display of molecules on silently genetically encoded nanoscale carriers for determining synergistic molecular interactions
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
EP3615550A1 (en) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof
WO2018224636A1 (en) 2017-06-09 2018-12-13 Vib Vzw Glutamine dehydrogenase inhibitors for use in muscle regeneration
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
CA3099077A1 (en) 2017-07-13 2019-01-17 Michael David FORREST Therapeutic modulators of the reverse mode of atp synthase
CA3069998A1 (en) 2017-07-17 2019-01-24 Vib Vzw Targeting synaptogyrin-3 in tauopathy treatment
JP7670481B2 (ja) * 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
WO2019034868A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
WO2019034866A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
EP3701259A1 (en) 2017-10-26 2020-09-02 VIB vzw Podoplanin positive macrophages
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
EP3746105A4 (en) 2018-01-29 2022-05-18 Ohio State Innovation Foundation CYCLIC PEPTIDYLIN HIBITORS OF THE CAL-PDZ-BINDING DOMAIN
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
CA3095582A1 (en) 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes
WO2019217682A1 (en) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
GB201808835D0 (en) 2018-05-30 2018-07-11 Bicyclerd Ltd Ligands and methods of selecting binding targets for such
GB201810325D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810320D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
GB201810327D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
GB201810316D0 (en) * 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201810329D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
US12391939B2 (en) 2018-07-23 2025-08-19 The Governors Of The University Of Alberta Genetically-encoded bicyclic peptide libraries
WO2020023620A1 (en) * 2018-07-25 2020-01-30 Trustees Of Boston College Methods and compositions of chemically modified phage libraries
US11655468B2 (en) 2018-07-25 2023-05-23 The Trustees Of Boston College Methods and compositions of chemically modified phage libraries
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
GB201819659D0 (en) 2018-12-03 2019-01-16 Vib Vzw Cancer regression by inducing a regeneration-like reponse
GB201820316D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for IL-17
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
SG11202106081YA (en) * 2018-12-13 2021-07-29 Bicycletx Ltd Bicyclic peptide ligands specific for mt1-mmp
GB201820320D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for FAPalpha
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
EP3897849A1 (en) * 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
GB201900530D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
GB201900525D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for caix
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
GB201900527D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for integrin avb3
GB201900528D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for integrin AVB3
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2020178574A1 (en) 2019-03-04 2020-09-10 Bicyclerd Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
US20220184222A1 (en) 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
KR20220007098A (ko) 2019-05-09 2022-01-18 바이사이클티엑스 리미티드 Ox40에 특이적인 이환식 펩티드 리간드
EP3976067A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
WO2020239945A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
EP4010352B1 (en) 2019-08-07 2023-10-18 Gyros Protein Technologies AB A method for modification of peptides immobilized on a solid support by traceless reductively cleavable linker molecules
US20220275053A1 (en) 2019-08-13 2022-09-01 Bicycletx Limited Modified multimeric bicyclic peptide ligands
GB201912320D0 (en) 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
GB201914233D0 (en) 2019-10-02 2019-11-13 Bicyclerd Ltd Phage cyclisation assay
SI4464721T1 (sl) 2019-10-03 2025-08-29 Bicycletx Limited Heterotandemski biciklični peptidni kompleksi
GB201914872D0 (en) 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
CN114760988A (zh) 2019-11-27 2022-07-15 拜斯科技术开发有限公司 对EphA2具有特异性的双环肽配体和其用途
GB201918558D0 (en) * 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201918559D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201918557D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
EP4077349A1 (en) 2019-12-16 2022-10-26 BicycleTX Limited Bicyclic peptide ligands specific for il-17
CN110907422B (zh) * 2019-12-16 2021-07-06 吉林大学 基于Ti3C2的凝血酶适体传感器及其制备方法
GB202002705D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Anti-infective bicyclic peptide conjugates
GB202002706D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Pbp3 binding bicyclic peptide ligands
WO2021205161A1 (en) 2020-04-06 2021-10-14 Bicycletx Limited Bicyclic peptide ligands specific for tslp
WO2021220011A1 (en) 2020-05-01 2021-11-04 Bicycletx Limited Anti-infective bicyclic peptide conjugates
CN116018349A (zh) 2020-05-15 2023-04-25 拜斯科技术开发有限公司 抗感染的双环肽配体
EP4165414A1 (en) 2020-06-12 2023-04-19 BicycleTX Limited Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)
CN116348476A (zh) 2020-08-03 2023-06-27 拜斯科技术开发有限公司 基于肽的接头
CN111893577B (zh) * 2020-08-06 2022-03-22 厦门大学 基于4-羟基-2,6-二氟-1,3,5-苯三腈构建噬菌体展示环肽库的方法
WO2022038158A1 (en) 2020-08-17 2022-02-24 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
WO2022063947A1 (en) 2020-09-24 2022-03-31 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
GB202016331D0 (en) 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
CN116802190A (zh) 2020-11-13 2023-09-22 拜斯科技术开发有限公司 特异于转铁蛋白受体1（TfR1）的双环肽配体
EP4274843A1 (en) 2021-01-08 2023-11-15 BicycleTx Limited Anti-infective bicyclic peptide ligands
JP2024504068A (ja) * 2021-01-08 2024-01-30 バイスクルテクス・リミテッド 抗感染性二環式ペプチドリガンド
US20240108737A1 (en) 2021-01-08 2024-04-04 Bicycletx Limited Anti-infective bicyclic peptide ligands
AU2022206394A1 (en) 2021-01-08 2023-08-24 Bicycletx Limited Bicyclic peptide ligands specific for nk cells
JP2024503642A (ja) 2021-01-08 2024-01-26 バイスクルテクス・リミテッド 抗感染性二環式ペプチドリガンド
CA3207009A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
CA3206529A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Heterotandem bicyclic peptide complexes
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
US20250325469A1 (en) 2021-01-24 2025-10-23 Michael David FORREST Inhibitors of atp synthase - cosmetic and therapeutic uses
CN117241804A (zh) 2021-02-17 2023-12-15 非营利性组织佛兰芒综合大学生物技术研究所 在癌症治疗中slc4a4的抑制
JP2024509996A (ja) 2021-03-19 2024-03-05 バイスクルテクス・リミテッド Ｔｒｅｍ２に特異的な二環式ペプチドリガンド
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
US12150998B2 (en) 2021-04-20 2024-11-26 Bicycletx Limited Bicyclic peptide ligands specific for P-selectin
EP4380691A1 (en) 2021-08-06 2024-06-12 Institut Régional du Cancer de Montpellier (ICM) Methods for the treatment of cancer
WO2023031623A2 (en) 2021-09-03 2023-03-09 Bicycletx Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
AU2022357561A1 (en) 2021-10-01 2024-04-18 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof
GB202114279D0 (en) 2021-10-06 2021-11-17 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
GB202114282D0 (en) 2021-10-06 2021-11-17 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
GB202116263D0 (en) 2021-11-11 2021-12-29 Bicycletx Ltd Anti-infective bicyclic peptide ligands
GB202116266D0 (en) 2021-11-11 2021-12-29 Bicycletx Ltd Novel use
CN114166924B (zh) * 2021-12-03 2024-11-22 中国医学科学院北京协和医院 尿液蛋白标志物在诊断遗传性血管水肿中的用途
EP4469081A1 (en) 2022-01-24 2024-12-04 Cambridge Enterprise Limited Tau therapy
GB202206431D0 (en) 2022-05-03 2022-06-15 Bicycletx Ltd Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
WO2024009108A1 (en) 2022-07-07 2024-01-11 Bicycletx Limited Anti-infective bicyclic peptide ligands
WO2024160756A1 (en) 2023-01-30 2024-08-08 Vib Vzw Suppressors of tauopathies
IL322909A (en) 2023-03-09 2025-10-01 Bicycletx Ltd Synthesis of bicyclic toxin conjugates and their intermediates
WO2024248860A1 (en) 2023-06-01 2024-12-05 Bicycletx Limited Bicyclic peptide ligands specific for epha2 and uses thereof
EP4719481A1 (en) 2023-06-01 2026-04-08 BicycleTx Limited Bicyclic peptide ligands specific for nectin-4 and uses thereof
WO2024248859A1 (en) 2023-06-01 2024-12-05 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4 and uses thereof
EP4719480A1 (en) 2023-06-01 2026-04-08 BicycleTx Limited Bicyclic peptide ligands specific for epha2 and uses thereof
WO2024252336A1 (en) 2023-06-07 2024-12-12 Peptidream Inc. Peptide compositions targeting glypican-3 and uses thereof
JP2026525826A (ja) 2023-06-23 2026-08-04 バイスクルテクス・リミテッド Ｎｋ細胞に特異的な二環式ペプチドリガンド
GB202312685D0 (en) 2023-08-18 2023-10-04 Bicycletx Ltd Computer implemented method
CN122094701A (zh) 2023-09-01 2026-05-26 拜斯科技术开发有限公司 Tlr3结合双环肽配体
GB202313403D0 (en) 2023-09-01 2023-10-18 Bicycletx Ltd Polypeptide screening
EP4777136A1 (en) 2023-09-13 2026-07-22 BicycleTx Limited Bicyclic peptide ligands specific for nectin-4 and uses thereof
WO2025067347A1 (zh) * 2023-09-28 2025-04-03 深圳湾实验室坪山生物医药研发转化中心 噬菌体颗粒复合物、其制备方法及其用途
WO2025085724A1 (en) * 2023-10-18 2025-04-24 University Of Utah Research Foundation An enzymatic method for synthesis of interpeptide thioether crosslinks
GB202316970D0 (en) 2023-11-06 2023-12-20 Bicycletx Ltd Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
WO2025125648A1 (en) 2023-12-13 2025-06-19 Bicycletx Limited Bicyclic peptide complex for use in treating cancer
WO2025125809A1 (en) 2023-12-13 2025-06-19 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4 and uses thereof
WO2025125652A1 (en) 2023-12-13 2025-06-19 Bicycletx Limited Combination therapy for use in treating cancer
WO2025191096A1 (en) 2024-03-14 2025-09-18 Bicycletx Limited Bicyclic peptide
GB202410566D0 (en) 2024-07-19 2024-09-04 Bicycletx Ltd Computer implemented method
WO2026159271A1 (en) 2025-01-24 2026-07-30 Bicycletx Limited Bicyclic peptide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9313509D0 (en) * 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1998036743A1 (en) 1997-02-21 1998-08-27 Cypros Pharmaceutical Corporation Neuroprotective poly-guanidino compounds which block presynaptic n and p/q calcium channels
CA2347973C (en) * 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
EP1224327A4 (en) 1999-09-29 2004-09-08 Xenoport Inc COMPOSITIONS ON GENETICALLY REPLICABLE PRODUCTS AND METHODS FOR THEIR USE
EP1385984A4 (en) 2001-03-21 2007-06-13 Xenoport Inc COMPOUND PRESENTED ON AN ICOSAEDRIC PHAGE AND METHOD OF USE THEREOF
EP1504111A4 (en) 2002-04-19 2005-11-23 California Inst Of Techn LIBRARY OF MOLECULES OF NUCLEIC ACIDS AND PEPTIDES IN WHICH THE PEPTIDES CONTAIN NON-NATURAL AMINO ACID RESIDUES AND METHODS FOR THEIR PRODUCTION
EP1452868A2 (en) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
ES2428869T3 (es) * 2005-01-24 2013-11-12 Pepscan Systems B.V. Compuestos de unión, compuestos inmunógenos y peptidomiméticos
WO2006095345A2 (en) 2005-03-08 2006-09-14 Ramot At Tel-Aviv University Ltd. Targeted drug-carrying bacteriophages
US20100322945A1 (en) * 2006-07-26 2010-12-23 Peter Timmerman Immunogenic compounds and protein mimics
WO2008074895A1 (en) * 2006-12-21 2008-06-26 Cytos Biotechnology Ag Circular ccr5 peptide conjugates and uses thereof

Also Published As

Publication number Publication date
EP2653543A1 (en) 2013-10-23
US20140187757A1 (en) 2014-07-03
EP2257624B9 (en) 2012-08-01
ATE555200T1 (de) 2012-05-15
ES2383191T3 (es) 2012-06-19
JP6074574B2 (ja) 2017-02-08
AU2009211253A1 (en) 2009-08-13
DK2474613T3 (da) 2014-10-06
US20150166988A1 (en) 2015-06-18
EP2474613B2 (en) 2022-02-16
CA2714477A1 (en) 2009-08-13
ES2383191T9 (es) 2012-10-16
DK2257624T3 (da) 2012-05-29
EP2653545A1 (en) 2013-10-23
JP2015109856A (ja) 2015-06-18
PT2257624E (pt) 2012-05-29
US20100317547A1 (en) 2010-12-16
AU2009211253B2 (en) 2014-11-06
WO2009098450A3 (en) 2009-10-29
US9670484B2 (en) 2017-06-06
ES2509959T5 (en) 2024-12-19
EP2653544A1 (en) 2013-10-23
JP2011514803A (ja) 2011-05-12
WO2009098450A2 (en) 2009-08-13
EP2474613B1 (en) 2014-07-16
EP2474613A1 (en) 2012-07-11
US9657288B2 (en) 2017-05-23
PL2257624T3 (pl) 2012-09-28
DK2257624T5 (da) 2012-09-10
EP2257624A2 (en) 2010-12-08
CA2714477C (en) 2018-10-16
JP6075658B2 (ja) 2017-02-08
US8680022B2 (en) 2014-03-25
EP2257624B1 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
De Veer et al. Cyclotides: from structure to function
Fetse et al. Recent advances in the development of therapeutic peptides
Qi et al. Mirror-image protein and peptide drug discovery through mirror-image phage display
Northfield et al. Disulfide-rich macrocyclic peptides as templates in drug design
Wang et al. Designing macrocyclic disulfide-rich peptides for biotechnological applications
ES2383191T3 (es) Métodos y composiciones
Baeriswyl et al. Polycyclic peptide therapeutics
ES2647076T3 (es) Peptidomiméticos de horquilla beta
ES2287206T3 (es) Proceso para el desarrollo de mini-proteinas de union.
ES2242620T3 (es) Estructuras peptidicas para exhibir bibliotecas de giros de un fago.
EP3107928B1 (en) Blood brain barrier shuttle
AU2016256226A1 (en) Novel inhibitors of the enzyme activated factor XII (FXIIa)
ES2552944T3 (es) Peptidomiméticos de horquilla beta como antagonistas de CXCR4
Lesner et al. Sunflower trypsin inhibitor 1 as a molecular scaffold for drug discovery
BRPI0117190B1 (pt) composto, composição farmacêutica, processo para a fabricação de um composto e uso do mesmo
ES2957258T3 (es) Peptidomiméticos de horquilla beta como inhibidores selectivos de elastasa
WO2014103203A1 (ja) 微小タンパク質の骨格構造に基づく分子ライブラリ
ES2453540T3 (es) Peptidomiméticos de horquilla beta fijados a patrón con actividad inhibitoria de proteasa
Smith et al. Cyclotides: a patent review
Wan et al. Inhibition of the norepinephrine transporter by χ‐conotoxin dendrimers
Schirra et al. Structure and folding of potato type II proteinase inhibitors: circular permutation and intramolecular domain swapping
JP5053991B2 (ja) ペプチド安定化化合物とスクリーニング方法
Chen et al. Phage selection of mono-and bicyclic peptide ligands
Angell et al. Peptide Discovery: Lead Generation
Padhy et al. Rational design of peptides and protein molecules in drug discovery